Rapporteurs and Co-Rapporteurs are members of the European Medicines Agency\u2019s scientific committees who take the lead in preparing the scientific assessment of a medicinal product. In the centralised procedure, they coordinate the review of a marketing authorisation application and draft the assessment reports on which the committee bases its opinion. These roles leverage the expertise of national competent authorities within an EU-wide organised assessment procedure.<\/p>\n
When a scientific committee assesses a medicinal product for human use, it appoints a Rapporteur from among its members; a second member may be designated as Co-Rapporteur. The appointment is made with due regard to the expertise available. The aim is an independent assessment with the appropriate scientific fit. Members and experts draw on the scientific assessment and resources of their national competent authorities.<\/p>\n
These roles do not exist only in the Committee for Medicinal Products for Human Use. For advanced therapy medicinal products, Rapporteurs and, where applicable, Co-Rapporteurs are appointed from the Committee for Advanced Therapies; in addition, CHMP coordinators support the assessment. For risk-management tasks and safety-related referral procedures, Rapporteurs and Co-Rapporteurs may be appointed from the Pharmacovigilance Risk Assessment Committee.<\/p>\n
The Rapporteur and Co-Rapporteur teams review the evidence submitted by the applicant. This includes quality, non-clinical and clinical data, the benefit\u2013risk assessment and, where necessary, aspects of risk management. Their initial reports are submitted to committee members for scientific review. Feedback from peer reviewers and other committees is incorporated into the further assessment.<\/p>\n
After the applicant responds to the committee\u2019s questions, both teams reassess the additional information. They may recommend inspections and participate in the scientific preparation of further procedural steps. Their reports are therefore central working documents, but not the marketing authorisation decision itself. The scientific opinion is adopted by the competent committee; the European Commission then takes the decision on the marketing authorisation.<\/p>\n
EMA Rapporteurs and Co-Rapporteurs are committee roles under EU pharmaceutical law. They are not to be equated with the reporting Member State in the authorisation procedure for clinical trials under Regulation (EU) No 536\/2014. There, one Member State coordinates the assessment of a specific clinical trial application together with the Member States concerned. The legal basis, the procedure and the subject matter are different.<\/p>\n
Nor does the designation of a Rapporteur imply a national unilateral decision. The work is discussed in the EMA\u2019s scientific committees and complemented by the expertise available within the European network. The Co-Rapporteur is not merely a substitute without an independent task, but participates as a second scientific assessment instance. In certain procedures, however, a Co-Rapporteur may be appointed only where needed.<\/p>\n
The dual role supports scientific cross-checking within the assessment. It brings two national teams of expertise and resources into a shared European committee process and makes differing scientific perspectives visible early on. At the same time, independence requirements apply: national authorities may not issue instructions to the appointed committee members that are incompatible with their individual tasks or the EMA\u2019s responsibilities. The scientific discussion thus remains anchored in the Union-wide committee procedure.<\/p>\n
For applicants, consistency of the overall narrative is particularly important. The assessment reports make relationships between individual dossier modules transparent; clinical conclusions must therefore align with quality data, safety evaluations and the proposed product information.<\/p>\n
A transparent scientific rationale therefore supports both an efficient review and the later traceability of the committee opinion. It should explicitly identify key uncertainties and link them to the analyses submitted.<\/p>\n
For clinical development programmes, Rapporteurs and Co-Rapporteurs are important because their assessment shapes the committee\u2019s questions and thus the evidence requirements for a marketing authorisation application. Study protocols, clinical study reports, statistical analyses and safety data must therefore be not only complete, but also provide a coherent scientific rationale for the proposed benefit\u2013risk profile. Unclear endpoint definitions, inconsistent data or missing justifications increase the effort required for follow-up questions and additional submissions.<\/p>\n
Full-service CROs such as Mediconomics support the dossier-ready preparation of clinical evidence through project management, monitoring, data management, biostatistics, pharmacovigilance and medical writing. This includes quality review of study documentation, structured provision of data analyses, preparation of scientific justifications and coordination of responses to regulatory questions that may arise from the assessment groups\u2019 reports.<\/p>\n
Do Rapporteurs grant EU marketing authorisation?<\/strong><\/p>\n No. They lead the scientific assessment; the competent committee adopts the opinion, and the European Commission takes the marketing authorisation decision.<\/p>\n Do these roles exist only in the CHMP?<\/strong><\/p>\n No. The CAT and PRAC can also appoint Rapporteurs and Co-Rapporteurs for their respective remits.<\/p>\n Is a Co-Rapporteur always required?<\/strong><\/p>\n The Regulation allows the appointment of a second member; the specific composition depends on the procedure and committee concerned.<\/p>\n Rapporteurs and Co-Rapporteurs are members of the European Medicines Agency\u2019s scientific committees who take the lead in preparing the scientific assessment of a medicinal product. In the centralised procedure, they coordinate the review of a marketing authorisation application and draft the assessment reports on which the committee bases its opinion. These roles leverage the expertise […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[20],"class_list":["post-8074","glossary","type-glossary","status-publish","hentry","glossary-cat-regulatory-affairs-zulassung"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8074\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=8074"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=8074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n